The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Co-occurring gene alterations associated with efficacy of osimertinib in EGFR-mutated lung cancer: Based on a large-scale genomic screening project (LC-SCRUM-Asia).
 
Yuji Shibata
Speakers' Bureau - AstraZeneca Japan; Bristol-Myers Squibb; Lilly Japan; Ono Pharmaceutical; Pfizer
 
Shingo Matsumoto
No Relationships to Disclose
 
Shunta Mori
No Relationships to Disclose
 
Tetsuya Sakai
Honoraria - AstraZeneca Japan; Chugai Pharma
 
Hiroki Izumi
Honoraria - Ono Yakuhin
Patents, Royalties, Other Intellectual Property - Amgen
 
Hibiki Udagawa
Honoraria - AstraZeneca
Research Funding - Takeda
 
Kaname Nosaki
Honoraria - AstraZeneca; Chugai Pharma; Janssen; Lilly; MSD; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Daiichi Sankyo/UCB Japan
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); MSD K.K (Inst); Takeda (Inst)
 
Yoshitaka Zenke
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Lilly; MSD Oncology; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - AstraZeneca (Inst); Merck Serono (Inst); MSD (Inst)
 
Kiyotaka Yoh
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Janssen; Kirin Pharmaceuticals; Lilly Japan; Novartis; Taiho Pharmaceutical
Consulting or Advisory Role - Chugai Pharma
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Lilly Japan (Inst); MSD (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Haruko Daga
Honoraria - Chugai/Roche; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Chugai/Roche (Inst); Lilly (Inst)
 
Atsuhisa Tamura
No Relationships to Disclose
 
Jun Sakakibara-Konishi
No Relationships to Disclose
 
Shoichi Kuyama
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Company; Chugai Pharma; Lilly Japan; MSD; Nippon Kayaku; Pfizer; Taiho Pharmaceutical
 
Naoki Furuya
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly; Novartis; Pfizer; Taiho Pharmaceutical
 
Atsushi Nakamura
Honoraria - AstraZeneca; Chugai Pharma; Kyowa Kirin; Lilly Japan; Novartis; Taiho Pharmaceutical; Thermo Fisher Scientific
 
Masato Shingyoji
No Relationships to Disclose
 
Kazumi Nishino
Honoraria - AstraZeneca Japan; Chugai Pharma; Lilly Japan; Merck; Nippon Boehringer Ingelheim; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Janssen; Pfizer
 
Terufumi Kato
Employment - Lilly (I)
Honoraria - Amgen; AstraZeneca; Chugai Pharma; Daiichi Sankyo; GlaxoSmithKline; Lilly; Merck KGaA; Merck Sharp & Dohme; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - AstraZeneca; Lilly; Merck Serono; MSD; Pfizer
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Chugai Pharma (Inst); Haihe Biopharma (Inst); Lilly (Inst); Merck KGaA (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Takeda (Inst); Turning Point Therapeutics (Inst)
 
Susumu Kobayashi
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Takeda
Research Funding - Boehringer Ingelheim; MiNA Therapeutics; Taiho Pharmaceutical
 
Koichi Goto
Honoraria - Amgen; Amoy Diagnostics; AstraZeneca Japan; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb K.K.; Chugai Pharma; DAIICHI SANKYO Co., Ltd.; Eisai; Guardant Health; Janssen; Lilly Japan; Merck; Novartis; Ono Pharmaceutical; Otsuka; Takeda
Consulting or Advisory Role - Amgen; Bayer; Janssen; Lilly Japan; Medpace; Takeda
Research Funding - Amgen; AstraZeneca Japan; Boehringer Ingelheim; Bristol-Myers Squibb K.K.; Chugai Pharma; DAIICHI SANKYO Co., Ltd.; Eisai; Ignyta; Janssen; Kissei Pharmaceutical; Kyowa Kirin Co., Ltd.; Lilly Japan; Loxo; MEDICAL & BIOLOGICAL LABORATORIES CO., LTD.; Merck; Merus; MSD K.K.; NEC Corporation; Ono Pharmaceutical; Pfizer; Shanghai HaiHe Pharmaceutical; Spectrum Pharmaceuticals; Sumitomo Dainippon Pharma Co., Ltd.; Sysmex; Taiho Pharmaceutical; Takeda; Thermo Fisher Scientific; Turning Point Therapeutics